1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443–459.
2. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116–120.
3. Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 2019;133:1313–1324.
4. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med 2013;369:1915–1925.
5. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated burkitt lymphoma. J Clin Oncol 2020;38:2519–2529.
6. Evens AM, Danilov A, Jagadeesh D, et al. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood 2021;137:374–386.
7. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46:218–223.
8. O’Conor GT, Davies JN. Malignant tumors in African children: with special reference to malignant lymphoma. J Pediatr 1960;56:526–535.
9. Burkitt D. A children’s cancer dependent on climatic factors. Nature 1962;194:232–234.
10. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964;1:702–703.
11. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 1967;157:1064–1065.
12. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 1972;237:33–34.
13. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824–7827.
14. Kafuko GW, Burkitt DP. Burkitt’s lymphoma and malaria. Int J Cancer 1970;6:1–9.
15. Robbiani DF, Bothmer A, Callen E, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008;135:1028–1038.
16. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. rev., Vol. 2. Lyon, France: IARC, 2017.
17. Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 2018;132:254–263.
18. de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt’s lymphoma from Ugandan prospective study. Nature 1978;274:756–761.
19. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer 2010;126:1732–1739.
20. Ziegler JL, Drew WL, Miner RC, et al. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet 1982;2:631–633.
21. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430–4438.
22. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006;354:2431–2442.
23. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419–2430.
24. Wagener R, Bens S, Toprak UH, et al. Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of “MYC-negative” Burkitt lymphoma. Haematologica 2020;105(4):e202–e205.
25. Gonzalez-Farre B, Ramis-Zaldivar JE, Salmeron-Villalobos J, et al. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 2019;104:1822–1829.
26. Wagener R, Seufert J, Raimondi F, et al. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 2019;133:962–966.
27. López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun 2019;10:1459–1459.
28. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991;88:5413–5417.
29. Reutter K, Sandmann S, Rohde J, et al. Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma. Leukemia 2021;35:639–643.
30. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323–1334.
31. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725–734.
32. Li M, Chen D, Shiloh A, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648–653.
33. Gong C, Krupka JA, Gao J, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell 2021;81(19):4059–4075.e11.
34. Nascimento EM, Cox CL, MacArthur S, et al. The opposing transcriptional functions of Sin3a and c-Myc are required to maintain tissue homeostasis. Nat Cell Biol 2011;13:1395–1405.
35. Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012;44:1316–1320.
36. Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44:1321–1325.
37. Giulino-Roth L, Wang K, MacDonald TY, et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 2012;120:5181–5184.
38. Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood 2019;134:1598–1607.
39. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989;56:777–783.
40. Kabrani E, Chu VT, Tasouri E, et al. Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells. Blood 2018;132:2670–2683.
41. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008;9:405–414.
42. Muppidi JR, Schmitz R, Green JA, et al. Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. Nature 2014;516:254–258.
43. Duan S, Cermak L, Pagan JK, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012;481:90–93.
44. Pighi C, Cheong T-C, Compagno M, et al. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Adv 2021;5:5239–5257.
45. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997;276:589–592.
46. Piccaluga PP, De Falco G, Kustagi M, et al. Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 2011;117:3596–3608.
47. Kaymaz Y, Oduor CI, Yu H, et al. Comprehensive transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences. Mol Cancer Res 2017;15:563–576.
48. Wilson WH, Bromberg JEC, Stetler-Stevenson M, et al. Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 2014;99:1228–1235.
49. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol 2015;33:2112–2118.
50. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–3068.
51. Olszewski AJ, Jakobsen LH, Collins GP, et al. Burkitt lymphoma international prognostic index. J Clin Oncol 2021;39:1129–1138.
52. Diviné M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005;16:1928–1935.
53. Alderuccio JP, Olszewski AJ, Evens AM, et al. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv 2021;5:2852–2862.
54. Zayac AS, Evens AM, Danilov A, et al. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica 2021;106:1932–1942.
55. Frazer JK, Li KJ, Galardy PJ, et al. Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. Br J Haematol 2019;185:374–377.
56. Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv 2021;5:3913–3918.
57. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19:697–704.
58. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 1986;4:1219–1226.
59. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt’s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986;4:1732–1739.
60. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925–934.
61. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294–3306.
62. Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med 2020;382:2207–2219.
63. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100:1438–1448.
64. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248–2260.
65. Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood 2015;126:160–166.
66. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 2014;124:3870–3879.
67. Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10 002. Br J Haematol 2014;165:102–111.
68. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569–1580.
69. Chamuleau M, Stenner F, Chitu D, et al. R-CODOX-M/R-IVAC versus dose-adjusted (DA)-EPOCH-R in patients with newly diagnosed high-risk Burkitt lymphoma; first results of a multi-center randomized HOVON/SAKK trial. Presented at the 27th Congress of the European Hematology Association, Vienna and virtual, June 9–17, 2022. abstract.
70. Ozuah NW, Lubega J, Allen CE, El-Mallawany NK. Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa. Blood Adv 2020;4:4007–4019.
71. Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol 2018;182:859–869.
72. Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 2017;92:E114–E117.
73. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012;22:167–179.
74. Wilke AC, Doebele C, Zindel A, et al. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood 2022;139:538–553.
75. Zhang W, Yang J, Zhou C, et al. Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. Blood 2020;135:2425–2427.